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Abstract: Natural and synthetic triterpenoids have been shown to kill cancer cells via multiple mech-
anisms. The therapeutic effect and underlying mechanism of the synthetic triterpenoid bardoxolone 
methyl (C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; CDDO-Me) on 
esophageal cancer are unclear. Herein, we aimed to investigate the anticancer effects and underly-
ing mechanisms of CDDO-Me in human esophageal squamous cell carcinoma (ESCC) cells. Our 
study showed that CDDO-Me suppressed the proliferation and arrested cells in G
2
/M phase, and 
induced apoptosis in human ESCC Ec109 and KYSE70 cells. The G
2
/M arrest was accompanied 
with upregulated p21Waf1/Cip1 and p53 expression. CDDO-Me significantly decreased B-cell 
lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP 
ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax). 
Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of 
the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) 
signaling pathway. There were interactions between the autophagic and apoptotic pathways in Ec109 
and KYSE70 cells subject to CDDO-Me treatment. CDDO-Me also scavenged reactive oxygen 
species through activation of the nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) pathway 
in Ec109 and KYSE70 cells. CDDO-Me inhibited cell invasion, epithelial–mesenchymal transition, 
and stemness in Ec109 and KYSE70 cells. CDDO-Me significantly downregulated E-cadherin but 
upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and 
KYSE70 cells. CDDO-Me significantly decreased the expression of octamer-4, sex determining 
region Y-box 2 (Sox-2), Nanog, and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1), all 
markers of cancer cell stemness, in Ec109 and KYSE70 cells. Taken together, these results indicate 
that CDDO-Me is a promising anticancer agent against ESCC. Further studies are warranted to 
explore the molecular targets, efficacy and safety of CDDO-Me in the treatment of ESCC.
Keywords: CDDO-Me, esophageal squamous cell carcinoma, cell cycle, apoptosis, autophagy, 
EMT, stemness, Akt, mTOR
Introduction
Esophageal cancer is the eighth most frequent cancer, and is the sixth leading cause of 
cancer-related death worldwide. It is a growing health concern that is expected to increase 
in incidence by 140% by 2025.1 There were an estimated 482,300 new esophageal cancer 
cases and 406,800 deaths globally in 2008.2 Incidence rates vary internationally by nearly 
16-fold, with the highest rates observed in Southern and Eastern Africa and Eastern Asia, 
and the lowest rates in Western and Middle Africa and Central America in both males 
and females.2 According to the National Cancer Institute, it was estimated that there were 
correspondence: shu-Feng Zhou 
Department of Pharmaceutical sciences, 
college of Pharmacy, University of south 
Florida, 12901 Bruce B. Down Boulevard, 
Tampa, Fl 33612, Usa
Tel +1 813 974 6276
Fax +1 813 905 9885
email szhou@health.usf.edu
Jia-Xuan Qiu
Department of Oral and Maxillofacial surgery, 
The First Affiliated Hospital of Nanchang 
University, 17 Yongwaizheng st, nanchang 
330006, Jiangxi, People’s republic of china
Tel +86 791 8869 2531
Fax +86 791 8869 2745
email qiujiaxuan@163.com
Journal name: Drug Design, Development and Therapy
Article Designation: Original Research
Year: 2015
Volume: 9
Running head verso: Wang et al
Running head recto: The anticancer mechanism of CDDO-Me in esophageal cancer
DOI: http://dx.doi.org/10.2147/DDDT.S73493
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
994
Wang et al
18,170 new esophageal cancer cases and 15,450 deaths from 
esophageal cancer in the USA in 2014.3 The age-adjusted inci-
dence of esophageal cancer in the USA is 4.4 per 100,000 men 
and women per year based on 2007–2011 case numbers. This 
disease is three to four times more common among men than 
among women. In People’s Republic of China, the estimated 
age-adjusted incidence rate of esophageal cancer in 2008 was 
16.7 per 100,000 population.4 About half of all cases globally 
occur in People’s Republic of China. Esophageal cancer is the 
19th most common cancer in Europe, with around 45,900 new 
cases diagnosed in 2012 (1% of the total). In 2011, there were 
8,332 new cases of esophageal cancer in the UK, 5,582 (67%) 
in men and 2,750 (33%) in women. The two main subtypes 
of esophageal cancer are squamous cell carcinoma, which is 
more common in the developing countries, and adenocarci-
noma, which is more common in the developed countries. The 
risk factors of esophageal squamous cell carcinoma (ESCC) 
include tobacco, alcohol, very hot drinks, and a poor diet, 
while the most common causes of the adenocarcinoma type 
are smoking tobacco, obesity, and acid reflux.5,6 Squamous 
cell carcinoma used to be the predominant histological type 
of esophageal cancer (ESCC), but now, adenocarcinoma has 
become the primary type of esophageal cancer in the USA, 
accounting for 80% of cases.6,7 Surgical resection is consid-
ered the mainstay of curative treatment for ESCC, though it 
can only be performed in a small subgroup of patients. Most 
patients diagnosed with advanced disease or recurrence within 
5 years after surgery will receive chemotherapeutic treatment. 
However, the response rate of traditional chemotherapy drugs, 
such as fluorouracil and cisplatin, is low (15%–20%) with 
remarkable side effects.5,6,8 Radiotherapy is given before, 
during, or after chemotherapy or surgery. Five-year survival 
rates for esophageal cancer are around 13%–18%.8 Thus, there 
is an urgent need to find more effective and safer therapeutic 
agents for esophageal cancer.
Naturally occurring triterpenoids like oleanolic acid and 
ursolic acid only show weak anti-inflammatory and anti-
carcinogenic activities.9 To increase their pharmacological 
efficacy, oleanolic acid has been modified to synthesize a 
series of new derivatives. The synthetic triterpenoids, such as 
2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and 
its derivatives including CDDO methyl ester (CDDO-Me; 
also called RTA 402, NSC 713200, and TP-155; its chemical 
structure is shown in Figure 1A), the methyl amide of CDDO, 
the ethyl amide of CDDO, and  CDDO-imidazolide, are com-
pounds originally developed for the prevention and treatment 
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Figure 1 (A) The chemical structure of cDDO-Me and (B) effects of cDDO-Me on the proliferation of ec109, KYse70, and het-1a cells determined by the MTT assay.
Notes: cells were treated with cDDO-Me at 0.01, 0.05, 0.25, 1.0, and 5.0 µM for 24 or 48 hours. Data are the mean ± sD of at least four independent experiments.
Abbreviations: cDDO-Me, methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; ic50, half maximal inhibitory concentration; sD, standard deviation; MTT, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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of inflammation and cancer.9,10 These synthetic triterpenoids 
are potent inhibitors of the de novo synthesis of inflammatory 
enzymes such as inducible nitric oxide synthase and induc-
ible cyclooxygenase 2.10 CDDO-Me has improved the renal 
function in patients with chronic kidney disease associated 
with type 2 diabetes in a Phase II study.11 However, a higher 
rate of cardiovascular events including heart failure, hospi-
talizations, and deaths with CDDO-Me than with placebo 
prompted termination of a Phase III trial in October 2012.12 
CDDO-Me is under clinical investigation for the treatment 
of pulmonary hypertension in the USA and chronic kidney 
disease associated with type 2 diabetes in Japan. Synthetic 
triterpenoids represent a novel group of small molecules 
currently being evaluated as anticancer agents. CDDO-Me 
(also known as bardoxolone methyl and RTA402) is more 
potent than CDDO in anticancer and cancer-preventive 
activities and in the activation of Kelch-like erythroid cell-
derived protein with CNC homology-associated protein 1/
nuclear factor (erythroid-derived 2)-related factor 2/antioxi-
dant response element (Keap1/Nrf2/ARE) pathway, which 
is involved in cytoprotection in the presence of excessive 
electrophiles or oxidative stress.9,13,14 The cytotoxic and 
antitumor effects of CDDO-Me have been reported in a 
variety of cancer cells in vitro and xenograft tumor-bearing 
nude mice.15–19 Cancer cells tested for CDDO-Me included 
prostate cancer, breast cancer, lung cancer, pancreatic can-
cer, osteosarcoma, and leukemia cell lines.18,19 CDDO-Me 
has also shown promising activities against several types 
of cancers in clinical trials. Nagaraj et al20 explored the 
efficacy and safety of CDDO-Me in 19 patients with 
pancreatic adenocarcinoma. Patients were treated intrave-
nously with gemcitabine (1,000 mg/m2) weekly on days 1, 
8, and 15. CDDO-Me was administered orally once daily 
for 21 days. Nine patients received a dose of 150 mg/day; 
two patients, 200 mg/day; six patients, 250 mg/day; and 
two patients, 300 mg/day. CDDO-Me abrogated the 
immune-suppressive effect of myeloid-derived suppressor 
cells and improved immune responses in cancer patients. 
CDDO-Me was well tolerated. Hong et al21 investigated 
the efficacy and safety of CDDO-Me in 47 patients 
with advanced solid tumors and lymphoma in a Phase I 
study. The maximum tolerated dose was established as 
900 mg/day. A complete tumor response occurred in a mantle 
cell lymphoma patient, and a partial response was observed in 
an anaplastic thyroid carcinoma patient.21 NAD(P)H:quinone 
oxidoreductase-1 (NQO1) mRNA levels were increased in 
peripheral blood mononuclear cells, while nuclear factor-κB 
(NF-κB) and cyclin D1 levels were decreased in tumor 
biopsies. CDDO-Me was tolerated well.
CDDO-Me acts as an activator of the Nrf2 pathway and an 
inhibitor of the NF-κB pathway. It contains α,β-unsaturated 
carbonyl groups on rings A and C that can generate revers-
ible adducts with the thiol groups of Cys residues in target 
proteins such as Keap1 and the inhibitor of κB kinase.9,13,14,18 
At low nanomolar concentrations, CDDO-Me protects 
the cells against oxidative stress via inhibition of reactive 
oxygen species (ROS) generation, while CDDO-Me at low 
micromolar concentrations induces apoptosis by increasing 
ROS and decreasing intracellular glutathione levels.9,13,14 The 
mechanisms for the anticancer activities of CDDO-Me are not 
fully understood. CDDO-Me has been shown to inhibit the 
proliferation of cancer cells, arrest cancer cells in G
2
/M phase, 
and induce apoptosis.22–24 Preclinical studies have suggested 
that the mitochondrial pathway, Keap1/Nrf2/ARE pathway, 
phosphoinositide 3-kinase (PI3K)/mammalian target of 
rapamycin (mTOR) pathway, Janus-activated kinase-1/signal 
transducer and activator of transcription-3 pathway, Notch 1 
signaling pathway, and many other signaling pathways are 
involved in the anticancer effect of CDDO-Me. However, the 
therapeutic effects of CDDO-Me on ESCC and the underlying 
mechanisms have not been reported. In this study, we evalu-
ated the therapeutic potential and the underlying mechanisms 
of CDDO-Me in human ESCC Ec109 and KYSE70 cells.
Materials and methods
chemicals and reagents
CDDO-Me (also called RTA 402, NSC 713200, and 
TP-155) was obtained from Cayman Chemical Inc. (Ann 
Arbor, MI, USA) with a purity of more than 98%. The 
PI3K inhibitor wortmannin, 5-(and 6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H
2
DCFDA), 
and the specific p38 mitogen-activated protein kinase (p38 
MAPK) inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-
hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] were bought 
from Invitrogen Inc. (Carlsbad, CA, USA). The protein kinase 
B (Akt) inhibitor MK-2206 and the mTOR inhibitor rapamy-
cin were purchased from Selleck Chemicals Inc. (Houston, 
TX, USA). The 5′-AMP-activated protein kinase (AMPK) 
inhibitor Compound C (dorsomorphin; 6-[4-(2-piperidin-1-
ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine) 
was obtained from Abcam Inc. (Cambridge, MA, USA). 
Trypsin, heat-inactivated fetal bovine serum (FBS), and peni-
cillin/streptomycin antibiotic mixture were from Mediatech 
Inc. (Manassas, VA, USA). The Roswell Park Memorial 
Institute medium (RPMI)-1640 medium was obtained from 
Coring Cellgro Inc. (Herndon, VA, USA). The bronchial 
epithelial cell growth medium (BEGM™)  BulletKit™ was 
bought from Lonza Group Ltd. Co. (Walkersville, MD, 
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USA). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), 
and Dulbecco’s phosphate-buffered saline (PBS) were pur-
chased from Sigma-Aldrich Co. (St Louis, MO, USA). The 
BD Pharmingen™ annexinV:phycoerythrin (PE) apoptosis 
detection kit was purchased from BD Biosciences Inc. (San 
Jose, CA, USA). Cyto-ID® Green Autophagy Detection Kit 
was obtained from Enzo Life Sciences Inc. (Farmingdale, 
NY, USA). QCM™ ECMatrix 96-well Cell Invasion Assay 
kit and polyvinylidene difluoride (PVDF) membrane were 
purchased from EMD Millipore Inc. (Bedford, MA, USA). 
Western blot substrate was obtained from Thermo Scientific 
Inc. (Hudson, NH, USA). Primary antibodies against human 
p21Waf1/Cip1, p53, cyclin B1, cyclin-dependent kinase 1 
(CDK1/Cdc2), the p53 upregulated modulator of apoptosis 
(PUMA), B-cell lymphoma 2 (Bcl-2), Bcl-2-like protein 4/
Bcl-2-associated X protein (Bax), Bcl-extra large (Bcl-xl), 
cytochrome c, cleaved caspase-3, cleaved caspase-9, poly 
ADP ribose polymerase (PARP), p38, phosphorylated (p-) 
p38 at Thr180/Tyr182, AMPK, p-AMPK at Thr 172, Akt, 
p-Akt at Ser473, mTOR, p-mTOR at Ser2448, PI3K, p-PI3K/
p85 at Tyr458, phosphatase and tensin homolog (PTEN), 
beclin1, microtubule-associated protein 1A/1B-light chain 3 
(LC3)-I, LC3-II, N-cadherin, E-cadherin, zona occludens 
protein 1 (ZO-1), β-catenin, Snail, Slug, zinc finger E-box-
binding homeobox 1 (TCF-8/ZEB1), vimentin, claudin 1, 
octamer-4 (Oct-4), B lymphoma Mo-MLV insertion region 
1 homolog (Bmi-1), Nanog, or sex determining region 
Y-box 2 (Sox-2) were all purchased from Cell Signaling 
Technology Inc. (Beverly, MA, USA). The antibodies against 
human Nrf2, heme oxygenase-1 (HO-1), NQO1, glutathione 
S-transferase (GST), histone H3, and β-actin were purchased 
from Santa Cruz Inc. (Santa Cruz, CA, USA).
cell lines, cell culture, and cDDO-Me 
treatment
The human ESCC cell line Ec109 was obtained from 
AddexBio Inc. (San Diego, CA, USA), and KYSE70 cells 
were purchased from Sigma-Aldrich Co. The normal human 
esophageal epithelial cell line Het-1A was bought from 
American Type Culture Collection (Manassas, VA, USA). 
The Het-1A cell line was derived  from human esophageal 
autopsy tissue by transfection with plasmid pRSV-T con-
sisting of the RSV-LTR promoter and the sequence encod-
ing the simian virus 40 large T-antigen. The Ec109 and 
KYSE70 cells were cultured in RPMI-1640 medium with 
100 U/mL penicillin, 100 µg/mL streptomycin, and 10% 
heat-inactivated FBS, and Het-1A was cultured in BEGM™ 
BulletKit™. All cells were maintained at 37°C in a saturated 
humidity atmosphere containing 95% air and 5% CO
2
. For 
experimental purposes, cells in exponential growth phase 
(approximately 70%–80% confluency) were used. The stock 
solution of CDDO-Me was prepared and stored at -20°C. 
The working solution of CDDO-Me was freshly diluted to 
the desired concentrations with culture medium. The final 
concentration of DMSO was at 0.05% (v/v).
cell viability assay
The cell viability analysis was performed by MTT assay as 
described previously.25 Briefly, Ec109, KYSE70, and Het-1A 
cells were seeded in a 96-well plate at a density of 8,000 cells 
each well and cultured overnight for attachment. The next 
day, the cells were treated with varying concentrations of 
CDDO-Me (0–5 µM) for 24 and 48 hours. Following drug 
treatment, the cells were incubated with 5 mg/mL MTT 
(10 µL/well) for 4 hours at 37°C. The reaction was termi-
nated by the addition of 100 µL DMSO. The absorbance 
was measured using a Synergy™ H4 Hybrid microplate 
reader (BioTek Inc., Winooski, VT, USA) at a wavelength of 
450 nm. The absorbance values were normalized by assigning 
the value of the control line in the medium without drug to 1.0 
and the value of the no-cell control to 0. The half inhibitory 
concentration (IC
50
) was defined as the CDDO-Me concentra-
tion required for decreasing the cells to 50% of the control 
value. Experiments were performed in at least triplicate.
Cell cycle analysis using flow cytometry
Flow cytometry was used to analyze the distribution of the 
cell cycle. The Ec109 and KYSE70 cells were incubated with 
various concentrations (0.25, 0.5, and 1.0 µM) of CDDO-Me 
for 24 hours. In a separate experiment, Ec109 and KYSE70 
cells were treated with 0.5 µM CDDO-Me for 4, 8, 12, 24, 
48, and 72 hours. After incubation, cells were harvested and 
fixed with 70% ethanol overnight at 4°C. Fixed cells were 
washed with PBS. Cells were then incubated with 1 U/mL of 
RNase A and 5 µg/mL of propidium iodide for 30 minutes at 
room temperature in the dark. Samples were analyzed for their 
DNA content by using an FACS Calibur flow cytometry with 
CellQuest™ software (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA). The number of cells in G
0
/G
1
, 
G
2
/M, and S phases was determined as a percentage of the total 
number of cells.
Quantification of cellular apoptosis 
using flow cytometry
Annexin V is a member of a calcium and phospholipid bind-
ing family of proteins with vascular anticoagulant activity. 
Annexin V is a 35-36 kDa Ca2+ dependent  phospholipid-binding 
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protein that has a high affinity for phosphatidylserine, and 
binds to cells with exposed phosphatidylserine. Annexin V 
can be conjugated to the fluorochrome PE, retaining its high 
affinity for phosphatidylserine and thus serving as a sensitive 
probe for flow cytometric analysis of apoptotic cells. Induc-
tion of apoptosis was assessed by the binding of annexin V to 
phosphatidylserine, which is externalized to the outer leaflet 
of the plasma membrane early during induction of apoptosis 
following the manufacturer’s protocols. In short, Ec109 
and KYSE70 cells were treated with CDDO-Me at various 
concentrations (0.25, 0.5, and 1.0 µM) for 24 hours or with 
0.5 µM CDDO-Me for different time intervals (4, 8, 12, 24, 
and 48 hours) and were resuspended in the binding buffer 
provided in the BD Pharmingen™ annexinV:PE apoptosis 
detection kit (BD Biosciences). Cells were mixed with 5 µL 
of annexin V:PE reagent and 5 µL of 7-amino-actinomycin D 
(7-AAD) and incubated for 15  minutes at room temperature 
in the dark. The double stained cells were analyzed by flow 
cytometer (Becton Dickinson Immunocytometry Systems) 
within 1 hour. By use of this detecting strategy, annexin 
V-negative/7-AAD-negative cells were defined as viable, 
annexin V-positive/7-AAD-negative cells as early apopto-
sis, annexin V-negative/7-AAD-positive cells as death, and 
annexin V-positive/7-AAD-positive cells as late apoptosis 
or necrosis.
Quantification of cellular autophagy 
using flow cytometry
Cellular autophagy was assessed using Cyto-ID® Green 
Autophagy Detection Kit (Enzo Life Sciences Inc.) by flow 
cytometry (LSRFortessa; BD Biosciences Inc.) according to 
the manufacturer’s instructions. The Cyto-ID® fluorescent 
reagents specifically detect the autophagic vacuoles formed 
during autophagy. In brief, Ec109 and KYSE70 cells were 
treated with CDDO-Me at various concentrations (0.25, 0.5, 
and 1.0 µM) for 24 hours. In separate experiment, Ec109 and 
KYSE70 cells were treated with 0.5 µM CDDO-Me for 4, 
8, 12, 24, and 48 hours. At the end of the treatment, sample 
was washed by resuspending the cell pellet in 1× assay buf-
fer (Enzo Life Sciences Inc.) and cells were collected by 
centrifugation as described previously.25 Cells were then 
resuspended in 250 µL phenol red-free culture medium 
(Invitrogen) containing 5% FBS, and 250 µL of the diluted 
Cyto-ID® Green stain solution was added to each sample 
and mixed well. Samples were then incubated at 37°C for 
30 minutes in dark and analyzed after wash with 1× assay 
buffer in the green channel (FL1) of an FACS Calibur flow 
cytometer (BD Biosciences). The flow cytometer collected 
10,000 events. The percentage of cells with Cyto-ID® staining 
was used to represent the relative formation or accumulation 
of autophagosomes. Results are expressed as the percentage 
of Cyto-ID®-positive cells of total live cells.
Quantification of cellular autophagy using 
confocal fluorescence microscopy
The autophagic level of Ec109 and KYSE70 cells was 
detected with Cyto-ID® Green Autophagy Detection Kit 
using confocal fluorescence microscopy. In brief, cells 
were plated on eight-well chamber slides, which were 
pre-coated with collagen I (BD Biosciences) at 40% con-
fluency. After incubation with control or various concen-
trations of CDDO-Me (0.25, 0.5, and 1.0 µM), the cells 
were washed twice with 1× assay buffer and stained with 
Cyto-ID® detection agent according to the manufacturer’s 
instructions. The live cell imaging was performed on a 
Leica TCS SP2 laser scanning confocal microscopy (Leica 
Microsystems, Wetzlar, Germany) equipped with a live 
cell chamber device to maintain 37°C in 5% CO
2
 condition 
during experiments. A standard FITC filter set for imaging 
the autophagic signal at wavelength of 405 nm/488 nm was 
used for the detection. The intensity of cell fluorescence 
was calculated for the corrected total cell fluorescence 
using the program ImageJ (National Institute of Health, 
Bethesda, MD, USA).
Western blotting analysis
Nuclear and cytoplasmic extracts for Western blotting assay 
were obtained by using NE-PER® Nuclear and Cytoplas-
mic Extraction Reagents (Thermo Fisher Scientific Inc., 
Rockford, IL, USA) following the manufacturer’s instruc-
tions. Total protein (cytoplasm plus nucleus) was obtained 
from cell lysates using the radioimmunoprecipitation assay 
buffer containing a protease inhibitor cocktail. Protein lev-
els were determined using the bicinchoninic acid assay kit. 
The samples (30 µg) were separated by 7%–12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis using 
a Mini-Protean® TGX™ Gel (BioRad Inc., Hercules, CA, 
USA) after boiling at 95°C for 5 minutes. The separated 
protein bands were then transferred to PVDF membranes. 
The membrane was incubated in a blocking buffer contain-
ing 5% nonfat dry milk in Tris-buffered saline and Tween 
20 (TBST) buffer for 1 hour at room temperature followed 
by overnight incubation at 4°C with the indicated primary 
antibody. Then, the membranes were washed with TBST and 
incubated with the appropriate secondary antibody (1:5,000) 
for 1 hour at room temperature. Visualization was performed 
using an enhanced chemiluminescence kit (BioRad Inc.) 
with electro-chemiluminescence substrate. Protein level 
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was normalized to the matching densitometric value of the 
internal control.
simultaneous determination of apoptosis 
and autophagy using flow cytometry
To explore the potential cross talk between CDDO-Me-
induced apoptosis and autophagy, we further determined 
the two modes of programmed cell death simultaneously 
after the combined treatment of different kinase inhibitors of 
autophagic pathway and CDDO-Me. In brief, the p38 MAP 
kinase inhibitor SB202190 (20 µM), the PI3K inhibitor 
wortmannin (10 µM), the Akt inhibitor MK-2206 (2.5 µM), 
the mTOR inhibitor rapamycin (0.5 µM), or the AMP-kinase 
inhibitor Compound C (10 µM) were used alone or in combi-
nation with 0.5 µM CDDO-Me to treat the cells for 24 hours. 
All these inhibitors were dissolved in DMSO at a final concen-
tration of 0.05% (v/v). At the end of the treatment, the cells 
were trypsinized and centrifuged at 1,000× g for 5 minutes 
to pellet the cells. The cells were divided into two equal 
volume samples, and washed with PBS. The apoptosis was 
detected using the annexinV:PE apoptosis detection kit and the 
autophagy was determined using Cyto-ID® Green Autophagy 
Detection Kit by flow cytometry (LSRFortessa™; BD Biosci-
ences Inc.) according to the manufacturer’s instructions at the 
same time. The flow cytometer collected 10,000 events.
intracellular rOs measurement
Intracellular ROS levels were assessed using CM-H
2
DCFDA 
ROS detection kit (Invitrogen Inc.) according to the manufac-
turer’s protocol. CM-H
2
DCFDA is cleaved by intracellular 
esterases to produce an impermeable, nonfluorescent active 
form, which further reacts with ROS to form a fluorescent 
product. In short, Ec109 and KYSE70 cells were seeded in 
a 96-well plate at a density of 1×104 cells/well. Cells were 
treated with CDDO-Me at different concentrations or evalu-
ated for different time intervals. After treatment, the cells 
were washed with PBS and then stained with CM-H
2
DCFDA 
(5 µM) for 30 minutes at 37°C, and analyzed for ROS levels 
using a Synergy™ H4 Hybrid microplate reader (BioTek 
Inc.) set at 485 nm and 530 nm excitation and emission wave-
lengths, respectively. After reading of ROS, cultures were 
then treated with Janus green, and cell counts were deter-
mined with the plate reader set to an absorbance of 610 nm, 
and ROS intensities were then corrected accordingly.
cell invasion assay
Cell invasion assay was performed using a QCM™ ECMatrix 
Cell Invasion kit (EMD Millipore Inc.; Cat #: ECM555). In 
brief, 1×105 cells in FBS-free RPMI were added to the top 
chamber, and 10% FBS in RPMI was added to the bottom 
chamber as a chemoattractant. The plate was incubated for 
24 hours at 37°C in a 5% CO
2
 incubator. At the end of the 
incubation period, the invasive cells were dissociated from the 
membrane with the cell detachment solution for 30 minutes at 
37°C. Next, 50 µL of lysis buffer/CyQuant® GR Dye Solution 
(1:75) was added to each well and incubated for 15 minutes 
at room temperature. Finally, 150 µL of the mixture was 
transferred to a new 96-well plate, and the fluorescence value 
was detected with a Synergy™ H4 Hybrid microplate reader 
(BioTek Inc.) using 480 nm/520 nm filter set.
statistical analysis
All statistical calculations were performed using Prism 5.0 
(GraphPad Software Inc., San Diego, CA, USA). Experimen-
tal values were presented as the mean ± standard deviation 
(SD) of the mean. Comparisons of multiple groups were 
evaluated by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s multiple comparison procedure. A P-value 
of 0.05 was considered statistically significant.
Results
cDDO-Me inhibits the proliferation 
of ec109 and KYse70 cells
To test the effect of CDDO-Me on the proliferation of human 
ESCC cells, 8,000 Ec109 and KYSE70 cells were plated in 
96-well plates overnight and then treated with CDDO-Me 
at concentrations of 0.01–5 µM for 24 and 48 hours. The 
normal human esophageal epithelial Het-1A cells were 
also treated with the same concentrations of CDDO-Me as 
human ESCC cell lines. At the end of the treatment, the 
viability of cultures was determined by the MTT assay. As 
shown in Figure 1B, treatment with CDDO-Me resulted 
in proliferative inhibition of ESCC and normal human 
esophageal epithelial cells in a concentration- and time-
dependent manner. When cells were treated with CDDO-Me 
at concentrations from 0.01 to 5 µM for 24 and 48 hours, 
the percentage of cellular viability of Ec109 was 102.8%–
13.5% and 102.9%–3.2%, respectively; the percentage 
of cellular viability of KYSE70 was 106.7%–11.6% and 
101.2%–8.9%, respectively; and the percentage of cellular 
viability of Het-1A was 103.5%–68.6% and 98.8%–48.4%, 
respectively. The IC
50
 of CDDO-Me in Ec109 cells was 
0.78 and 0.30 µM for 24- and 48-hour drug treatment, 
respectively (Figure 1B), and was 1.21 and 0.64 µM for 24- 
and 48-hour drug treatment in KYSE70 cells, respectively 
(Figure 1B). Moreover, the IC
50
 of CDDO-Me in Het-1A 
cells was 32.63 and 3.13 µM when cells were incubated for 
24 and 48 hours,  respectively (Figure 1B). These results 
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suggest that CDDO-Me suppresses the growth of both 
human ESCC cells in a concentration- and time-dependent 
manner. CDDO-Me shows a significantly higher antipro-
liferative activity in ESCC cells than in normal human 
esophageal epithelial cells. When the drug exposure time 
is increased, the sensitivity of normal human esophageal 
epithelial cells to CDDO-Me was greatly enhanced.
cDDO-Me induces g2/M arrest 
in ec109 and KYse70 cells
To identify the mechanisms behind the cell growth inhibition, 
we determined the effect of CDDO-Me on cell cycle progres-
sion. Ec109 and KYSE70 cells were treated with various 
concentrations of CDDO-Me (0.25, 0.5, and 1.0 µM) and 
analyzed using flow cytometry. As shown in Figure 2A, both 
Ec109 and KYSE70 cells were arrested in G
2
/M phase after 
incubation with CDDO-Me for 24 hours, especially at the 
high concentration. The percentage of cells arrested in G
2
/M 
phase was increased by 16.3% in Ec109 cells (P0.001 by 
one-way ANOVA) and 12.2% in KYSE70 cells (P0.01 by 
one-way ANOVA) at 1.0 µM of CDDO-Me in comparison to 
the control cells. Exposure of human ESCC cells to CDDO-Me 
significantly reduced the number of cells in G
1
 phase compared 
to the control cells treated with the control vehicle only. The 
number of cells in G
1
 phase was significantly reduced by 16.2% 
(P0.001 by one-way ANOVA) and 14.3% (P0.001 by 
one-way ANOVA) in Ec109 and KYSE70 cells, respectively, 
when treated with CDDO-Me at 1.0 µM. In addition, treat-
ment of Ec109 and KYSE70 cells with CDDO-Me at 0.5 µM 
significantly decreased the number of cells in S phase. The 
percentage of cells in S phase was decreased by 1.6% (P0.05 
by one-way ANOVA) and 6.6% (P0.001 by one-way 
ANOVA), respectively, in Ec109 and KYSE70 cells. A lower 
or higher concentration of CDDO-Me (0.25 and 1.0 µM) did 
not significantly affect the number of both Ec109 and KYSE70 
cells in S phase (P0.05 by one-way ANOVA).
Next, we evaluated the cell cycle-arresting effect of 
CDDO-Me at 0.5 µM on both Ec109 and KYSE70 cells 
with different incubation times in a separate experiment. 
Treatment of Ec109 cells with 0.5 µM CDDO-Me for 
4–72 hours significantly increased the percentage of cells in 
G
2
/M phase from 13.1% at basal level to 22.9% (P0.01 by 
one-way ANOVA; Figure 2B). The number of Ec109 cells in 
G
1
 phase significantly decreased from 76.0% at basal level to 
57.5% after 4–72-hour incubation with 0.5 µM CDDO-Me 
(P0.01 by one-way ANOVA; Figure 2B). However, there 
was no significant difference observed in the number of cells 
in S phase in the time course evaluation. For KYSE70 cells, 
CDDO-Me exhibited a differential effect on the cell cycle 
progression. Compared to the control cells, the percentage 
of cells in G
1
 phase was increased from 48.1% at basal level 
to 51.7% after 4–48-hour treatment with CDDO-Me and 
declined to 38.1% after 72-hour treatment with CDDO-Me, 
while 0.5 µM CDDO-Me treatment reduced the percentage 
of cells in S phase from 24.9% at basal level to 15.9% after 
4–24-hour incubation and the percentage of cells raised to 
39.8% after 48–72-hour incubation with CDDO-Me. There 
was a significant decrease in the percentage of KYSE70 cells 
in G
2
/M phase after treatment with CDDO-Me for 12 hours 
(P0.01 by one-way ANOVA; Figure 2B).
To delineate the molecular mechanism of CDDO-Me-
mediated G
2
/M arrest, we determined its effect on the key 
regulators of cell cycle including Cdc2 and cyclin B1 for 
G
2
-to-M phase transition26 using Western blotting assay. 
A significant decrease in the Cdc2 and cyclin B1 expres-
sion level was observed in human ESCC cells treated with 
CDDO-Me. In Ec109 cells, treatment with CDDO-Me at 
0.25, 0.5, and 1.0 µM for 24 hours significantly decreased 
the level of Cdc2 by 24.2%, 30.3%, and 44.9% (P0.05 
by one-way ANOVA; Figure 2C and D), and suppressed 
the expression of cyclin B1 by 14.4%, 46.1%, and 41.6%, 
respectively, compared to the control cells (P0.05 or 0.01 
by one-way ANOVA; Figure 2C and D). In KYSE70 cells, 
in comparison to the control cells, the expression level of 
Cdc2 was decreased 1.6-fold when treated with 1.0 µM 
CDDO-Me for 24 hours. In addition, there was a 42.1% 
and 55.7% reduction in the expression level of cyclin B1 in 
KYSE70 cells treated with CDDO-Me at 0.5 and 1.0 µM 
for 24 hours, respectively. Taken together, these results 
demonstrate that CDDO-Me arrests human ESCC cells in 
G
2
/M phase in a concentration- and time-dependent manner, 
with the involvement of Cdc2 and cyclin B1.
cDDO-Me upregulates p21Waf1/cip1 
and p53 expression in ec109 and KYse70 
cells
To further investigate the molecular mechanism of CDDO-
Me-mediated G
2
/M arrest, we determined the expression 
levels of p21Waf1/Cip1 and p53 in human ESCC cells 
by Western blot analysis. p21Waf1/Cip1 is a potent CDK 
inhibitor that binds to and inhibits the activity of cyclin–
CDK2, cyclin–CDK1, and cyclin–CDK4/6 complexes, and 
thus functions as a regulator of cell cycle progression.27 The 
expression of p21Waf1/Cip1 is tightly controlled by the 
tumor suppressor protein p53, through which this protein 
mediates the p53-dependent cell cycle arrest in response to 
a variety of stress stimuli.28 Our results showed that there 
was a substantial increase in the p21Waf1/Cip1 expression 
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level in Ec109 cells exposed to CDDO-Me. After incubation 
with 1.0 µM CDDO-Me, the expression level of p21Waf1/
Cip1 was increased 3.3-fold compared to control cells 
(P0.01 by one-way ANOVA; Figure 2C and D). In addi-
tion, there was a marked increase in the expression of p53 in 
a concentration-dependent manner in Ec109 cells. Treatment 
of Ec109 cells with CDDO-Me at 0.25, 0.5, and 1.0 µM for 
24 hours significantly increased the level of p53 by 94.7%, 
134.2%, and 188.2%, respectively (P0.05, 0.01 or 0.001 
by one-way ANOVA; Figure 2C and D).
Similarly, there was also a significant increase in the 
expression of p21Waf1/Cip1 in KYSE70 cells treated with 
CDDM-Me. Compared to the control cells, there was a 
2.1-fold increase in the expression of p21Waf1/Cip1 in 
KYSE70 cells treated with CDDO-Me at 0.5 µM (P0.01 by 
one-way ANOVA; Figure 2C and D). Similarly, the expres-
sion of p53 was also significantly increased in KYSE70 cells 
treated with CDDO-Me. CDDO-Me at 1 µM increased the 
expression level of p53 in KYSE70 cells by 64.9%, compared 
to the control cells (P0.05 by one-way ANOVA; Figure 2C 
and D). These results indicate that CDDO-Me increases the 
level of p21Waf1/Cip1 via upregulating p53, contributing to 
its cell cycle-arresting effect in human ESCC cells.
cDDO-Me induces the apoptosis 
of ec109 and KYse70 cells via activation 
of mitochondrial pathway
To elucidate whether CDDO-Me decreases cell survival 
through the induction of apoptosis in human ESCC cells, we 
examined the effects of CDDO-Me on apoptosis in Ec109 
and KYSE70 cells using flow cytometry. The number of 
apoptotic cells was first quantified by the binding of annexin 
V:PE to Ec109 and KYSE70 cells treated with CDDO-Me 
using flow cytometric analysis. As shown in Figure 3A, 
a small percentage of untreated Ec109 and KYSE70 cells 
bound annexin V:PE (5.3% and 5.6%, respectively). The per-
centage of annexin V:PE-binding Ec109 and KYSE70 cells 
markedly increased following treatment with CDDO-Me at 
concentrations of 0.25, 0.5, and 1 µM for 24 hours (Ec109: 
6.7%, 10.6%, and 26.0%; KYSE70: 15.4%, 20.2%, and 
25.2%, respectively).
Next, we tested the apoptotic effect of 0.5 µM CDDO-Me 
on Ec109 and KYSE70 cells with different incubation time 
intervals by flow cytometric analysis. The results showed 
that 0.5 µM CDDO-Me did not trigger the apoptotic effect 
in Ec109 cells. However, in KYSE70 cells, a time-dependent 
apoptotic effect was demonstrated in the analysis. The per-
centage of the apoptotic cells was increased from 4.9% at the 
basal level to 18.7% after 24-hour incubation with 0.5 µM 
CDDO-Me (Figure 3B).
Bcl-2, Bcl-xl, Bax, and PUMA are major proteins involved 
in the apoptosis-regulating pathways.29 To investigate the 
mechanisms underlying CDDO-Me-induced apoptosis, we 
examined the expression of these key proteins upon CDDO-Me 
treatment by Western blotting assay. Ec109 and KYSE70 
cells were exposed to different concentrations of CDDO-Me 
for 24 hours and cellular lysates were obtained for analysis. 
The results showed that CDDO-Me consistently decreased 
the level of Bcl-xl and Bcl-2 and increased the level of Bax 
and PUMA. Incubation of Ec109 cells with CDDO-Me at 
1.0 µM significantly decreased Bcl-xl and Bcl-2 expression 
level by 34.7% and 98.3%, respectively, compared to the 
control cells (P0.05, 0.01, or 0.001 by one-way ANOVA; 
Figure 3C and D), but significantly increased the level of 
Bax and PUMA by 90.9% and 33.5% (P0.05 or 0.01 
by one-way ANOVA; Figure 3C and D), respectively. Similarly, 
incubation of KYSE70 cells with CDDO-Me at 1.0 µM signifi-
cantly decreased Bcl-xl and Bcl-2 expression level by 62.6% and 
54.5% (P0.01 or 0.001 by one-way ANOVA; Figure 3C and 
D), respectively, compared to the control cells, but significantly 
increased the level of PUMA by 46.7% compared to the control 
cells (P0.01 or 0.001 by one-way ANOVA; Figure 3C and 
D). There was an increase in the expression level of Bax by 
CDDO-Me treatment at 0.5 µM in KYSE70 cells, whereas no 
such change was observed at 1.0 µM CDDO-Me.
In addition, the activation of caspases upon CDDO-Me 
treatment in human ESCC cells was also observed in the pres-
ent study. We detected the presence of cleaved caspase-9, 
caspase-3, and PARP by Western blotting assay with specific 
antibodies, and found that their activation was significantly 
triggered upon CDDO-Me treatment for 24 hours. In Ec109 
cells, the increase fold was 1.6 for cleaved caspase-9 and 
26.0 for cleaved PARP. The cleaved caspase-3 level did 
not change under CDDO-Me treatment during the period of 
monitoring. For KYSE70 cells, the increase fold was 3.0 for 
cleaved caspase-3, but the levels of cleaved caspase-9 and 
cleaved PARP were not affected by CDDO-Me.
Cytochrome c is a component of the electron transport 
chain in mitochondria and is involved in the initiation of 
apoptosis.30 The release of cytochrome c was evaluated in 
both Ec109 and KYSE70 cells in the current study. Treat-
ment of Ec109 and KYSE70 cells with CDDO-Me for 
24 hours significantly increased the release of cytochrome c. 
Taken together, CDDO-Me decreases cell survival through 
the induction of apoptosis via activation of mitochondrial 
pathway in human ESCC cells.
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Figure 3 CDDO-Me-induced apoptotic death in Ec109 and KYSE70 cells determined by measuring cellular DNA contents using flow cytometry.
Notes: (A) Percentages of specific cell populations showed in dot plots and apoptotic cells showed in bar graphs for Ec109 and KYSE70 cells treated with CDDO-Me at 
0.25–1.0 µM for 24 hours. (B) Percentages of specific cell populations showed in dot plots and apoptotic cells showed in bar graphs for Ec109 and KYSE70 cells treated with 
cDDO-Me at 0.5 µM for 4–48 hours. (C) representative blots of respective proteins measured to show the effect of cDDO-Me treatment on the expression levels of Bcl-xl, 
Bcl-2, Bax, PUMa, cytochrome c, cleaved caspase-3 (active), cleaved caspase-9 (active), ParP, and cleaved ParP in ec109 and KYse70 cells determined using Western 
blotting analysis. (D) Bar graphs showing the levels of Bcl-xl, Bcl-2, Bax, PUMa, cytochrome c, cleaved caspase-3 (active), cleaved caspase-9 (active), ParP, and cleaved ParP 
in ec109 and KYse70 cells. Data represent the mean ± sD of three independent experiments. β-actin was used as the internal control. *P0.05, **P0.01, and ***P0.001 
by one-way anOVa and Tukey’s post hoc test to compare the levels of the protein measured with the control cells treated with control vehicle only (0.05% DMsO, v/v).
Abbreviations: cDDO-Me, methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; sD, standard deviation; anOVa, analysis of variance; DMsO, dimethyl sulfoxide; 
ParP, poly aDP ribose polymerase; PUMa, p53 upregulated modulator of apoptosis; 7-aaD, 7-amino-actinomycin D; Pe, phycoerythrin; hr, hour.
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1005
The anticancer mechanism of cDDO-Me in esophageal cancer
cDDO-Me induces autophagy in ec109 
and KYse70 cells via inhibition of Pi3K/
mTOr pathway
To check if CDDO-Me induced autophagy in human ESCC 
cells and the underlying mechanisms, we evaluated the 
autophagic cell death in Ec109 and KYSE70 cells exposed to 
various concentrations of CDDO-Me using flow cytometric 
analysis. As shown in Figure 4A and B, a small percentage 
of autophagic cells were detected in untreated Ec109 and 
KYSE70 cells (1.1% and 2.7%, respectively). The percentage 
of autophagic cells in Ec109 and KYSE70 cells markedly 
increased following treatment with CDDO-Me at concentra-
tions of 0.25, 0.5, and 1 µM for 24 hours (Ec109 cells: 5.3%, 
6.1%, and 11.3%; and KYSE70 cells: 3.0%, 3.7%, and 6.8%, 
respectively).
Next, we tested the autophagic effect of 0.5 µM CDDO-Me 
on Ec109 and KYSE70 cells with different incubation time 
intervals by flow cytometric analysis. A time-dependent 
autophagic effect was demonstrated in both cell lines. The per-
centage of the autophagic cells was increased from 0.7% at the 
basal level to 44.2% after 24-hour incubation with CDDO-Me 
in Ec109 cells (Figure 4A and B). In KYSE70 cells, the 
number of the autophagic cells was increased 36.3-fold 
with 48-hour treatment of 0.5 µM CDDO-Me.
LC3 is one of the autophagy-related proteins participating 
in the process of autophagosome formation, and is frequently 
used as an autophagosome marker.31 To further confirm the 
autophagic effect of CDDO-Me on human ESCC cells, we 
examined the changes of LC3 after incubation with various 
concentrations of CDDO-Me using confocal microscopy. 
We demonstrated that the population of LC3-positive 
cells increased after incubation of human ESCC cells with 
CDDO-Me. Figure 4C clearly shows that after 24-hour incu-
bation with CDDO-Me, the cells had obvious increases in 
green punctate structures distributed in perinuclear regions 
and focally throughout the cytoplasm in Ec109 and KYSE70 
cells, whereas these structures were almost not observed in 
control cells. The intensity of fluorescence, which indicated 
the autophagic death of cells, was increased 3.3- and 3.9-
fold when treated with CDDO-Me at 0.25 and 0.5 µM for 
24 hours, respectively, in Ec109 cells. In KYSE70 cells, the 
intensity of fluorescence was increased by 53.0%, 80.4%, and 
132.8% when treated with 0.25, 0.5, and 1.0 µM CDDO-Me, 
respectively. In addition, Cyto-ID® Green reagent staining 
also showed that the relative fluorescence intensity of cells 
was increased in a time-dependent manner, indicating the 
occurrence of autophagy (Figure 4C). These results are 
consistent with the autophagic effect of CDDO-Me on human 
ESCC cells, which are detected by flow cytometric analysis 
in the same study.
As mTOR is a well-known regulator of autophagy,32 the 
involvement of mTOR signaling pathway in the initiation 
of autophagy in CDDO-Me-treated cells was further inves-
tigated using Western blotting analysis. CDDO-Me treatment 
led to a marked decrease in p-mTOR at Ser2448 in both 
Ec109 and KYSE70 cells. There was no significant change 
in the expression level of total mTOR in both cell lines when 
treated with CDDO-Me for 24 hours. Thus, a decreased ratio 
of p-mTOR/mTOR was observed in both cell lines when 
treated with different concentrations of CDDO-Me. In Ec109 
cells, the ratio of p-mTOR/mTOR was decreased from 0.7 
at basal level to 0.5, 0.3, and 0.2 when treated with 0.25, 
0.5, and 1 µM of CDDO-Me, respectively (P0.05 or 0.01 
by one-way ANOVA; Figure 4D and E). In KYSE70 cells, 
the ratio of p-mTOR/mTOR was decreased from 0.3 at basal 
level to 0.13, 0.12, and 0.06 when treated with 0.25, 0.5, and 
1 µM of CDDO-Me, respectively (P0.05, 0.01 or 0.001 by 
one-way ANOVA; Figure 4D and E).
To further explore the mechanism of CDDO-Me-induced 
autophagy in human ESCC cells, several key proteins of 
upstream signaling pathways of mTOR, such as PI3K, 
Akt, AMPK, p38 MAPK, and PTEN, were measured after 
CDDO-Me treatment by Western blotting assay. CDDO-Me 
treatment significantly decreased the levels of p-PI3K at 
Tyr458 and p-Akt at Ser473 but increased the levels of 
p-AMPK at Thr172, p-p38 MAPK at Thr180, and PTEN in a 
dose-dependent manner in both Ec109 and KYSE70 cells.
Additionally, the expression level of beclin 1 and 
LC3, two autophagy-related proteins, was also determined 
using Western blotting assay. Beclin 1 is an essential 
autophagic protein that contributes to the initial vesicle 
nucleation and formation of autophagosome.33 Figure 4D 
clearly shows that both CDDO-Me-treated cell types had 
a notable increase in beclin 1 expression levels compared 
to control cells. Treatment of Ec109 cells with CDDO-Me 
at 0.25, 0.5, and 1.0 µM significantly increased the level 
of beclin 1 by 30.0%, 77.5%, and 117.5%, respectively, 
compared to the control cells (P0.05 by one-way 
ANOVA; Figure 4D and E). In KYSE70 cells, the level 
of beclin 1 was increased by 38.0%, 71.4%, and 90.4% 
at 0.25, 0.5, and 1.0 µM CDDO-Me, respectively, com-
pared to the control cells (P0.05 by one-way ANOVA; 
Figure 4D and E).
The conversion of cytosolic LC3-I to membrane-bound 
LC3-II indicates autophagic activity.34,35 When autophagy is 
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Figure 4 CDDO-Me induces autophagy in Ec109 and KYSE70 cells determined by flow cytometry and confocal microscopy.
Notes: (A and B) Percentages of specific cell populations showed in dot plots and autophagic cells showed in bar graphs for Ec109 and KYSE70 cells treated with CDDO-Me 
at 0.25–1.0 µM for 24 hours, respectively; and percentages of specific cell populations showed in dot plots and autophagic cells showed in bar graphs for Ec109 and KYSE70 
cells treated with cDDO-Me at 0.5 µM for 4–48 hours, respectively. (C) cDDO-Me-induced autophagic death in ec109 and KYse70 cells determined by confocal microscopy. 
The level of autophagy was evaluated using a lysosome-specific fluorescence dye. Cells were treated with CDDO-Me at 0.25–1.0 µM for 24 hours or at 0.5 µM for different 
incubation times from 4 hours to 48 hours. The confocal microscopic images of autophagic ec109 and KYse70 cells (stained in green) are also shown. (D) effects of cDDO-Me 
treatment on the expression levels of p-Pi3K at Tyr458, Pi3K, p-aMPK at Thr172, aMPK, p-p38 at Thr180, p38, p-akt at ser473, akt, p-mTOr at ser2448, mTOr, PTen, 
beclin 1, LC3-I, and LC3-II in Ec109 and KYSE70 cells. Cellular lysates were analyzed by immunoblotting with respective first antibody followed by the second antibody. (E) Bar 
graphs showing the levels of the proteins in ec109 and KYse70 cells. The ratios of p-Pi3K, aMPK, p38, akt, and mTOr over the corresponding total protein and ratios of lc3-ii 
over lc3-i in ec109 and KYse70 cells are also shown. β-actin was used as the internal control. Data represent the mean ± sD of three independent experiments. *P0.05, 
**P0.01, and ***P0.001 by one-way anOVa and Tukey’s post hoc test to compare the levels of the protein measured with the control cells treated with the vehicle only.
Abbreviations: cDDO-Me, methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; sD, standard deviation; anOVa, analysis of variance; mTOr, mammalian target 
of rapamycin; hr, hour.
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induced, LC3-I is conjugated to phosphatidylethanolamine 
to form LC3-II, the 16-kDa form of the LC3 protein that is 
specific for the membranes of autophagosomes.34,35 There-
fore, the conversion of LC3-I to LC3-II is correlated with 
increased autophagic flux. In Figure 4D, the conversion 
of LC3-I to LC3-II was remarkably increased in Ec109 
cells after 24-hour incubation with CDDO-Me. CDDO-Me 
significantly increased the ratio of LC3-II over LC3-I from 
0.57 (basal) to 0.76–1.28 (P0.05 or 0.001 by one-way 
ANOVA; Figure 4D and E). However, the ratio of LC3-II/
LC3-I did not change significantly in KYSE70 cells. These 
data together demonstrate that CDDO-Me induces autophagy 
in human ESCC cells through suppression of mTOR signal-
ing pathway.
There is a crosstalk between cDDO-
Me-induced apoptotic and autophagic 
pathways in ec109 and KYse70 cells
Considering the paradoxical role of autophagy in promoting 
cell death or survival, we further treated human ESCC cells 
with several kinase inhibitors of autophagic pathway, includ-
ing p38 MAPK, PI3K, Akt, AMPK, and mTOR inhibitor, 
either alone or in combination with CDDO-Me to determine 
the crosstalk between CDDO-Me-induced apoptosis and 
autophagy. The apoptosis and autophagy were simultane-
ously determined by flow cytometry. The results demon-
strated that CDDO-Me predominantly induced apoptosis, 
with autophagy being the minor pathway in programmed 
cell death of Ec109 and KYSE70 cells. In Ec109 cells, 
the CDDO-Me-induced apoptosis was 6.7%, 10.7%, and 
26.0%, and autophagy was 5.3%, 6.1%, and 11.3% at 0.25, 
0.5, and 1.0 µM of CDDO-Me, respectively. In KYSE70 
cells, CDDO-Me-induced apoptosis was 15.3%, 20.2%, and 
25.2%, and autophagy was 3.0%, 3.7%, and 6.7% at 0.25, 
0.5, and 1.0 µM of CDDO-Me, respectively.
Next, we examined the effect of inhibition of the key 
kinases of the autophagic pathway on basal and CDDO-
Me-induced apoptosis in Ec109 and KYSE70 cells. Under 
the basal condition, treatment of ESCC cells with 20 µM 
SB202190 or 10 µM Compound C significantly enhanced 
both autophagy and apoptosis in human ESCC cells 
(Figure 5A–C). In Ec109 cells, the percentage of autophagic 
cells was increased 6.6- and 13.8-fold after the incubation 
with 20 µM SB202190 and 10 µM Compound C, respec-
tively. The percentage of apoptotic cells was increased 
4.0-fold after 24-hour incubation with 20 µM SB202190. 
In KYSE70 cells, the number of autophagic cells were 
increased by 1,664.8% when treated with 20 µM SB202190 
for 24 hours and apoptotic cells were increased by 292.9% 
when treated with 10 µM Compound C for 24 hours. In 
addition, 2.5 µM MK-2206 also enhanced the autophagy of 
KYSE70 cells. However, 10 µM wortmannin and 0.5 µM 
rapamycin had no impact on the basal level of autophagy 
and apoptosis in human ESCC cells (Figure 5A–C).
In the combination experiment, 10 µM wortmannin or 
10 µM Compound C significantly enhanced the CDDO-
Me-induced autophagy and apoptosis. 0.5 µM rapamycin 
or 2.5 µM MK-2206 significantly enhanced the CDDO-Me-
induced autophagy, while incubation with 20 µM SB202190 
significantly enhanced CDDO-Me-induced apoptosis. In 
Ec109 cells, the percentage of CDDO-Me-induced autophagic 
cells was increased 2.2-, 2.4-, and 3.0-fold when incubated 
with 10 µM Compound C, 0.5 µM rapamycin, or 2.5 µM 
MK-2206, respectively (Figure 5A–C). The percentage of 
CDDO-Me-induced apoptotic cells was increased 2.8-and 
6.4-fold after 24-hour incubation with 10 µM Compound C 
and 20 µM SB202190, respectively. In KYSE70 cells, the 
number of CDDO-Me-induced autophagic cells was increased 
by 254.2%, 260.4%, and 1,397.6% when treated with 0.5 µM 
rapamycin, 10 µM wortmannin, or 2.5 µM MK-2206 for 
24 hours, respectively, and CDDO-Me-induced apoptotic cells 
were increased by 58.1%, 69.5%, and 146.7% when treated 
with 10 µM wortmannin, 10 µM Compound C, or 20 µM 
SB202190 for 24 hours, respectively (Figure 5A–C).
These results demonstrate that there are interactions 
between the autophagic and apoptotic pathways in Ec109 
and KYSE70 cells subject to CDDO-Me treatment. PI3K and 
AMPK play an important role in the interplay for their dual 
modulating functions in both CDDO-Me-induced autophagy 
and apoptosis.
cDDO-Me inhibits the generation of 
intracellular rOs and activates the nrf2 
pathway in ec109 and KYse70 cells
To further explore the mechanism of CDDO-Me-induced cell 
proliferation inhibition and programmed cell death including 
both apoptosis and autophagy, we determined the effect of 
CDDO-Me on intracellular ROS level in Ec109 and KYSE70 
cells treated with 0.1, 0.25, 0.5, and 1.0 µM CDDO-Me for 
24 hours. The intracellular level of ROS was significantly 
decreased by CDDO-Me in both cell lines. In Ec109 cells, 
treatment with CDDO-Me at 0.1 and 1.0 µM for 24 hours 
reduced the intracellular level of ROS by 21.1% and 36.8%, 
respectively, compared to the control cells (P0.01 or 0.001 
by one-way ANOVA; Figure 6A). Similarly, incubation of 
KYSE70 cells with CDDO-Me at 0.1, 0.25, and 0.5 µM for 
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Figure 5 effect of sB202190, wortmannin, MK-2206, rapamycin, and compound c on cDDO-Me-induced apoptosis and autophagy in ec109 and KYse70 cells determined 
using flow cytometry.
Notes: (A) Dot plots showing the number of cells in different phases and bar graphs showing the percentages of apoptotic cells after ec109 and KYse70 cells were treated 
with 20 µM sB202190, 10 µM wortmannin, 2.5 µM MK-2206, 0.5 µM rapamycin, or 10 µM compound c alone or in combination with 0.5 µM cDDO-Me. (B) Dot plots 
showing the number of cells in different phases and bar graphs showing the percentages of autophagic cells after ec109 and KYse70 cells were treated with 20 µM sB202190, 
10 µM wortmannin, 2.5 µM MK-2206, 0.5 µM rapamycin, or 10 µM compound c alone or in combination with 0.5 µM cDDO-Me. (C) Bar graphs showing the percentages 
of apoptotic cells and autophagic cells after treatment with 20 µM sB202190, 10 µM wortmannin, 2.5 µM MK-2206, 0.5 µM rapamycin, or 10 µM compound c alone or in 
combination with 0.5 µM cDDO-Me. Data represent the mean ± sD of three independent experiments. *P0.05, **P0.01, and ***P0.001 by one-way anOVa.
Abbreviations: cDDO-Me, methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; sD, standard deviation; anOVa, analysis of variance.
24 hours significantly decreased the intracellular level of ROS 
by 16.8%, 18.3%, and 20.7%, respectively, compared to the 
control cells (P0.01 by one-way ANOVA; Figure 6A).
In addition, the intracellular ROS levels in Ec109 and 
KYSE70 cells treated with 0.5 µM CDDO-Me at different time 
intervals were also determined in this study. In Ec109 cells, the 
intracellular ROS level was decreased by 48.9% and 44.3% 
when incubated with 0.5 µM CDDO-Me for 48 and 72 hours, 
respectively (P0.01 by one-way ANOVA; Figure 6A). 
In KYSE70 cells, the intracellular ROS level was decreased 
from 31.2% to 40.3% when treated with 0.5 µM CDDO-Me for 
12–72 hours (P0.01 by one-way ANOVA; Figure 6A).
Nrf2 is a nuclear factor that controls the expression and 
coordinated induction of a battery of genes that encode detox-
ifying enzymes, drug transporters, anti-apoptotic proteins, 
and proteasomes.36 Under basal conditions, Nrf2 is retained 
in the cytoplasm by Keap1 and cullin 3 with a half-life of 
only 20 minutes, which is degraded rapidly by ubiquitination. 
Under oxidative stress, critical cysteine residues in Keap1 are 
disrupted, and Nrf2 will build up and then translocate to the 
nucleus where it forms a heterodimer with a small Maf pro-
tein and binds to a DNA promoter and initiates transcription 
of antioxidative genes.36 To further investigate the molecular 
mechanisms of the ROS-scavenging effects of CDDO-Me 
in human ESCC cells, we examined if CDDO-Me activated 
the Nrf2 pathway. Nuclear proteins were isolated and ana-
lyzed by Western blotting assay using anti-Nrf2 antibody. 
The expression levels of the target genes of Nrf2 including 
HO-1, NQO1, and GST were also analyzed using Western 
blotting assay. Cytosolic (c)-Nrf2, nuclear (n)-Nrf2, HO-1, 
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NQO1, and GST expression levels were increased in both 
Ec109 and KYSE70 cells treated with a low concentration 
of CDDO-Me as compared to the control cells. In Ec109 
cells, the HO-1 expression level was elevated 1.4-fold when 
treated with 0.5 µM CDDO-Me for 24 hours (P0.05 by 
one-way ANOVA; Figure 6B & C). The NQO1 and GST 
levels were elevated 1.5-fold (P0.05 or 0.01 by one-way 
ANOVA; Figure 6B & C) and 1.7-fold (P0.05 by one-way 
ANOVA; Figure 6B & C), respectively, when treated with 
0.25 µM CDDO-Me for 24 hours. In KYSE70 cells treated 
with 0.25 µM CDDO-Me, the ratio of n-Nrf2/c-Nrf2, HO-1, 
NQO1, and GST levels was increased by 135.4%, 200.8%, 
96.7%, and 152.5%, respectively (P0.05, 0.01, or 0.001 
by one-way ANOVA; Figure 6B & C).
In addition, c-Nrf2, n-Nrf2, HO-1, NQO1, and GST 
expression levels were also examined with the treatment of 
0.5 µM CDDO-Me at different incubation time intervals. The 
accumulation of Nrf2 in nucleus was detected after 48-hour 
incubation with CDDO-Me in both cell lines. However, 
the time-dependent activation of Nrf2 target genes was not 
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Figure 6 effect of cDDO-Me on the intracellular reactive oxygen species (rOs) production and its target genes including HO-1, NQO1, and GST in ec109 and KYse70 cells.
Notes: (A) Bar graphs showing the intracellular rOs levels in ec109 and KYse70 cells when treated with cDDO-Me at 0.1–1.0 µM for 24 hours or at 0.5 µM for 
0.5–72 hours. (B) effect of cDDO-Me treatment at 0.25–1.0 µM on the expression levels of cytosolic nrf2, nuclear nrf2, hO-1, nQO1, and gsT in ec109 and KYse70 cells. 
(C) effect of cDDO-Me treatment for 4–48 hours on the expression levels of cytosolic (c-) nrf2, nuclear (n-) nrf2, hO-1, nQO1, and gsT in ec109 and KYse70 cells. cellular 
lysates were analyzed by immunoblotting with respective first antibody followed by the second antibody. Representative blots of the proteins measured. Bar graphs showing the 
levels of the proteins in ec109 and KYse70 cells. histone h3 was used as the internal control for nuclear protein. β-actin was used as the internal control. (D) effect of cDDO-
Me treatment for 4–48 hours on the expression levels of cytosolic nrf2, nuclear nrf2, hO-1, nQO1, and gsT in ec109 and KYse70 cells. cellular lysates were analyzed by 
immunoblotting with respective first antibody followed by the second antibody. Representative blots of the proteins measured. (E) Bar graphs showing the levels of the proteins 
in ec109 and KYse70 cells. The ratios of cytosolic nrf2, nuclear nrf2, hO-1, nQO1, and gsT in ec109 and KYse70 cells with different time course are also shown. histone 
h3 was used as the internal control for nuclear protein. β-actin was used as the internal control. Data represent the mean ± sD of three independent experiments. *P0.05, 
**P0.01, and ***P0.001 by one-way anOVa and Tukey’s post hoc test to compare the levels of the protein measured with the control cells treated with the vehicle only.
Abbreviations: cDDO-Me, methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; rOs, reactive oxygen species; sD, standard deviation; anOVa, analysis of 
variance; hr, hour; c, cytosolic; n, nuclear.
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observed. The dramatically reduced expression level of HO-1, 
NQO1, and GST was observed in both Ec109 and KYSE70 
cells after 48-hour incubation with 0.5 µM CDDO-Me 
(Figure 6D & E). The reason for this is unknown. These 
enzymes may also be regulated by other genes such as nuclear 
receptors, which might be modulated by CDDO-Me.
cDDO-Me suppresses ec109 and 
KYse70 cell invasion in vitro
To determine the effect of CDDO-Me on the invasive poten-
tial of human ESCC cells, the QCM™ 96-well cell inva-
sion assay was performed. The invasive potential of cancer 
cells in this assay was determined by the ability of cells to 
invade ECM layer, the major components of the basement 
membrane. As demonstrated in Figure 7A, both Ec109 and 
KYSE70 cells had a tendency of higher invasive phenotype at 
the base level. The ratio of the fluorescence value for Ec109 
cells cultured in media with FBS over that without FBS was 
2.7, while this ratio for KYSE70 cells was 3.3. The invasive 
capacity of both cell lines was reduced by CDDO-Me. After 
incubation with 0.5 µM CDDO-Me for 24 hours, the ratio 
of the fluorescence value for Ec109 cells cultured in media 
with FBS over that without FBS was reduced to 1.7, while 
this ratio for KYSE70 cells was reduced to 1.5. These results 
suggest that CDDO-Me attenuates the invasive capacity of 
human ESCC cells in vitro.
cDDO-Me inhibits the eMT phenotype 
of ec109 and KYse70 cells
Epithelial–mesenchymal transition (EMT) is integral in devel-
opment, wound healing, and stem cell behavior, and contrib-
utes pathologically to fibrosis and cancer progression.37,38 It is 
a fine-tuned process regulated by a number of proteins that are 
strategically distributed in the nuclear and cytosolic compart-
ments of cancer cells.39 To further examine the mechanisms 
of the therapeutic effect of CDDO-Me on human ESCC 
cells, we evaluated the change of EMT-associated markers in 
Ec109 and KYSE70 cells exposed to CDDO-Me using West-
ern blotting assay. The most critical and well-studied EMT 
molecule is E-cadherin.37 The E-cadherin was upregulated by 
the treatment with CDDO-Me; however, the statistical sig-
nificance was achieved only in Ec109 cells. The E-cadherin 
expression level was increased 2.6-fold when treated with 
1.0 µM CDDO-Me for 24 hours, compared to the control cells 
(P0.05 by one-way ANOVA; Figure 7B and C).
Snail, Slug, and TCF-8/ZEB1 are the critical members 
of the family of transcription factors that repress E-cadherin, 
leading to upregulation of mesenchymal genes.37 These three 
markers were downregulated after the incubation with various 
concentrations of CDDO-Me for 24 hours in both Ec109 and 
KYSE70 cells. In Ec109 cells, the Snail and Slug expression 
levels were reduced by 44.4% and 53.3% (P0.05 by one-
way ANOVA; Figure 7B and C), respectively, when treated 
with 1.0 µM CDDO-Me for 24 hours, compared to the control 
cells. The TCF-8/ZEB1 expression level was not impacted 
by CDDO-Me. In KYSE70 cells, the Snail, Slug, and TCF-8/
ZEB1 expression levels were reduced by 71.4%, 61.5%, and 
76.2% (P0.05 or 0.001 by one-way ANOVA; Figure 7B 
and C), respectively, when treated with 1.0 µM CDDO-Me 
for 24 hours, compared to the control cells. N-cadherin and 
vimentin are important mesenchymal markers,37 which were 
also evaluated in this study. The N-cadherin and vimentin 
levels in Ec109 cells were decreased 2.1-fold and 1.6-fold 
(P0.05 or 0.01 by one-way ANOVA; Figure 7B and C), 
respectively, when treated with 1.0 µM CDDO-Me for 
24 hours, compared to the control cells. In KYSE70 cells, the 
expression levels of N-cadherin and vimentin were decreased 
by 1.5- and 2.1-fold (P0.05 or 0.01 by one-way ANOVA; 
Figure 7B and C), respectively.
In addition, the expression levels of the tight junction 
proteins ZO-1 and claudin 1 were also determined in Ec109 
and KYSE70 cells exposed to CDDO-Me. In Ec109 cells, 
both ZO-1 and claudin 1 were upregulated when treated with 
CDDO-Me for 24 hours; however, only the elevated level 
of ZO-1 achieved statistical significance. Treatment with 
1.0 µM CDDO-Me significantly increased the level of ZO-1 
by 107.2% (P0.05 by one-way ANOVA; Figure 7B and C). 
In KYSE70 cells, 1.0 µM of CDDO-Me significantly increased 
the level of ZO-1 and claudin 1 by 95.7% and 233.3% 
(P0.05 or 0.01 by one-way ANOVA; Figure 7B and C), 
respectively.
β-Catenin is a transcription factor in the Wnt signaling 
pathway and is involved in the regulation of cell adhesion, 
and it is typically more abundant in epithelial-like cells.40 
β-Catenin binds to cadherin receptor intracellular cytoplasmic 
tail domains, acting as an integral component of a protein com-
plex in adherens junctions that help cells maintain epithelial 
layers.40 The expression level of β-catenin was downregulated 
by 68.2% and 30.8% (P0.05, 0.01, or 0.001 by one-way 
ANOVA; Figure 7B and C) in Ec109 and KYSE70 cells, 
respectively, when treated with 1.0 µM CDDO-Me for 
24 hours, compared to the control cells.
In a separate experiment, we evaluated the impact 
of different incubation times with 0.5 µM CDDO-Me 
on the expression of EMT-related markers. The change 
in the expression of these EMT-related markers showed 
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the same trend as the concentration-dependent effect of 
CDDO-Me in Ec109 and KYSE70 cells. The most sig-
nificant change of these markers occurred in the longer 
incubation time interval of CDDO-Me. In Ec109 cells, 
E-cadherin, ZO-1, and claudin 1 were upregulated by 
95.0%, 101.6%, and 63.4%, respectively, while Snail, 
Slug, and vimentin were downregulated by 78.3%, 59.2%, 
and 50.9%, respectively, after 48-hour incubation with 
0.5 µM CDDO-Me, compared to the control cells (Figure 
7D and E). In KYSE70 cells, there was 53.2%, 326.1%, 
and 221.0% increase in E-cadherin, ZO-1, and claudin 1, 
respectively, whereas there was a 73.6% reduction in Slug 
after 48-hour incubation with 0.5 µM CDDO-Me (Figure 
7D and E). These results suggested that CDDO-Me inhibits 
EMT in human ESCC cells.
cDDO-Me attenuates the stemness 
of ec109 and KYse70 cells
There is increasing evidence that diverse tumors are hierar-
chically organized and sustained by a distinct subpopulation 
of cancer stem cells.41–43 On the basis of the cancer stem 
cell hypothesis, a tumor may be sustained by a subset of 
cancer cells with stem-cell-like features that have the abil-
ity for self-renewal and pluripotency. Because stemness is a 
characteristic hallmark of malignant disease, which has an 
impact on the efficiency of cancer therapy, chemotherapeutic 
agents that block the stemness have been an important focus 
in the field of cancer chemotherapy.41,42 Oct-4, a member 
of the POU family, is considered to be an important cancer 
stem cell marker and essential transcription factor during 
embryogenesis.44 Sox-2 is a member of the Sox (SRY-
related HMG box) gene family that encodes transcription 
factors with a single HMG DNA-binding domain, which is 
expressed in many types of cancer.45 Nanog is believed to 
function in conjunction with other factors such as Oct-4 and 
Sox-2 to form an embryonic stem cell identity.46 Bmi-1 is a 
transcriptional repressor that belongs to the polycomb-group 
family of proteins that are involved in hematopoiesis, regula-
tion of proliferation, and senescence.47 It is a potent repressor 
of retinoblastoma and the p53 pathway with an important 
role in tumorigenesis. To further explore the mechanisms 
of therapeutic effect of CDDO-Me on human ESCC cells, 
several selected stemness markers, including Oct-4, Sox-2, 
Nanog, and Bmi-1, were analyzed using Western blotting 
assay. The results showed that CDDO-Me significantly 
decreased the expression of Oct-4, Sox-2, Nanog, and Bmi-1 
in Ec109 and KYSE70 cells. Incubation of Ec109 cells 
with CDDO-Me at 1.0 µM significantly decreased Oct-4, 
Sox-2, Nanog, and Bmi-1 expression levels by 44.3%, 
53.4%, 26.8%, and 44.2%, respectively, compared to the 
control cells (Figure 8A and B). In KYSE70 cells, there was 
3.1-fold, 1.7-fold, and 2.1-fold decrease in Oct-4, Nanog, and 
Bmi-1, respectively, when treated with 1.0 µM CDDO-Me 
for 24 hours (Figure 8A and B).
In a separate experiment, we evaluated the effects of 
different incubation times with 0.5 µM CDDO-Me on the 
stemness of human ESCC cells. In Ec109 cells, Oct-4, 
Nanog, and Bmi-1 were downregulated by 44.8%, 38.0%, and 
41.6%, respectively, after 48-hour incubation with 0.5 µM 
CDDO-Me, compared to the control cells (Figure 8C and D). 
The decreased expression level of Sox-2 was observed only 
after 12-hour incubation of 0.5 µM CDDO-Me. Sox-2 was 
decreased by 73.3% when compared to the basal level. In 
KYSE70 cells, all four stemness makers were suppressed 
with the 48-hour treatment with CDDO-Me; however, the 
decreased level of Sox-2 did not achieve statistical signifi-
cance. Oct-4, Nanog, and Bmi-1 were downregulated 2.2-, 
1.4-, and 1.4-fold, respectively, after 48-hour incubation 
with 0.5 µM CDDO-Me, compared to the control cells 
(Figure 8C and D). These results indicate that CDDO-Me 
suppresses the stemness of human ESCC cells.
Discussion
There is an increased interest in the use of CDDO-Me as a new 
anticancer agent. However, the effect of CDDO-Me on ESCC 
remains unclear. Furthermore, the effects of CDDO-Me on 
autophagy, EMT, and stemness in solid cancer cells have 
not been reported. In this study, we found that CDDO-Me 
effectively suppressed the proliferation and induced G
2
/M 
cell cycle arrest and apoptosis in human ESCC cells. We 
also found that CDDO-Me scavenged ROS level through 
activation of the Nrf2 pathway. For the first time, our study 
has demonstrated that CDDO-Me induced autophagy and 
suppressed EMT and stemness, contributing to the anticancer 
activity of CDDO-Me. To the best of our knowledge, this 
is the first study that has confirmed the autophagy-inducing 
ability of CDDO-Me in solid cancer cells.
A number of studies have shown that CDDO-Me dis-
played a remarkable concentration-dependent inhibitory 
effect on the proliferation and growth of many cancer cell 
lines.19,48,49 The present study showed that CDDO-Me sig-
nificantly inhibited the growth of Ec109 and KYSE70 cells. 
However, CDDO-Me did not show remarkable inhibition 
on the proliferation of the normal human epithelial Het-1A 
cells compared to the human ESCC cells. Difference in the 
proliferation inhibitory effect between human ESCC and 
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1020
Wang et al
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
Relative level of Sox-2
Relative level of Nanog
Relative level of Bmi-1
Relative level of Oct-4
Relative level of Sox-2
Relative level of Nanog
Relative level of Bmi-1
Relative level of Oct-4
C
D
D
O
-M
e 
(µ
M
)
C
D
D
O
-M
e 
(µ
M
)
O
ct
-4
0
0
0.
25
4 3 2 1
0
0.
25
0.
5
1.
0
0
0.
25
0.
5
1.
0
0
0.
25
0.
5
1.
0
0
0.
25
0.
5
1.
0
0
0
0.
25
0.
5
1.
0
0.
25
0.
5
1.
0
0
4
** **
**
*
**
*
**
*
**
**
*
**
3 2 1 0
4 3 2 1 0
45 3 2 1 0 3 2 1 0
3 2 1 0
0.
8
1.
0
0.
6
0.
4
0.
2
0.
0
0
0.
25
0.
5
1.
0
0.
8
1.
0
0.
6
0.
4
0.
2
0.
0
0
0.
25
0.
5
1.
0
0.
25
0.
5
0.
5
1.
0
1.
0
45
 k
D
a
43
 k
D
a
42
 k
D
a
35
 k
D
a
45
 k
D
a
E
c1
09
 c
el
ls
E
c1
09
 c
el
ls
B
A
K
Y
S
E
70
 c
el
ls
K
Y
S
E
70
 c
el
ls
B
m
i-
1
N
an
o
g
S
o
x-
2
β
-a
ct
in
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1021
The anticancer mechanism of cDDO-Me in esophageal cancer
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Tr
ea
tm
en
t 
ti
m
e 
(h
r)
Relative level of Sox-2
Relative level of Nanog
Relative level of Bmi-1
Relative level of Oct-4
Relative level of Sox-2
Relative level of Nanog
Relative level of Bmi-1
Relative level of Oct-4
4 3 2 1
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0
4
8
12
24
48
0 4 3 2 1 0
4 3 2 1 0
45 3 2 1 045 3 2 1 0
0.
8
1.
0
0.
6
0.
4
0.
2
0.
0
1.
5
2.
0
1.
0
0.
5
0.
0
2.
0
2.
5
1.
5
1.
0
0.
5
0.
0
**
**
* **
*
*
*
**
**
**
**
*
**
*
**
*
**
**
*
45
 k
D
a
48
24
12
4
0
8
48
24
12
4
0
8
43
 k
D
a
42
 k
D
a
35
 k
D
a
45
 k
D
a
E
c1
09
 c
el
ls
E
c1
09
 c
el
ls
D
C
K
Y
S
E
70
 c
el
ls
K
Y
S
E
70
 c
el
ls
Ti
m
e 
(h
r)
O
ct
-4
B
m
i-
1
N
an
o
g
S
o
x-
2
β
-a
ct
in
Fi
gu
re
 8
 e
ffe
ct
 o
f c
D
D
O
-M
e 
on
 t
he
 e
xp
re
ss
io
n 
le
ve
ls
 o
f s
te
m
ne
ss
 m
ar
ke
rs
 in
cl
ud
in
g 
O
ct
-4
, B
m
i-1
, n
an
og
, a
nd
 s
ox
-2
 in
 e
c1
09
 a
nd
 K
Y
se
70
 c
el
ls
.
N
ot
es
: (
A
) e
ffe
ct
 o
f c
D
D
O
-M
e 
tr
ea
tm
en
t 
at
 0
.2
5–
1.
0 
µM
 fo
r 
24
 h
ou
rs
 o
n 
th
e 
ex
pr
es
si
on
 le
ve
ls
 o
f s
te
m
ne
ss
 m
ar
ke
rs
, i
nc
lu
di
ng
 O
ct
-4
, B
m
i-1
, n
an
og
, a
nd
 s
ox
-2
 in
 e
c1
09
 a
nd
 K
Y
se
70
 c
el
ls
. (
B
) B
ar
 g
ra
ph
s 
sh
ow
in
g 
th
e 
ch
an
ge
s 
of
 O
ct
-4
, 
Bm
i-1
, n
an
og
, a
nd
 s
ox
-2
 in
 e
c1
09
 a
nd
 K
Y
se
70
 c
el
ls
. (
C
) 
T
he
 t
im
e 
co
ur
se
 w
he
n 
ce
lls
 w
er
e 
tr
ea
te
d 
w
ith
 1
.0
 µ
M
 c
D
D
O
-M
e 
fo
r 
4–
48
 h
ou
rs
. (
D
) 
Ba
r 
gr
ap
hs
 s
ho
w
in
g 
th
e 
ch
an
ge
s 
of
 O
ct
-4
, B
m
i-1
, n
an
og
, a
nd
 s
ox
-2
 in
 e
c1
09
 a
nd
 K
Y
se
70
 
ce
lls
 t
re
at
ed
 w
ith
 1
.0
 µ
M
 C
D
D
O
-M
e 
fo
r 
4–
48
 h
ou
rs
. C
el
lu
la
r 
ly
sa
te
s 
w
er
e 
an
al
yz
ed
 b
y 
im
m
un
ob
lo
tt
in
g 
w
ith
 r
es
pe
ct
iv
e 
fir
st
 a
nt
ib
od
y 
fo
llo
w
ed
 b
y 
th
e 
se
co
nd
 a
nt
ib
od
y.
 R
ep
re
se
nt
at
iv
e 
bl
ot
s 
of
 t
he
 p
ro
te
in
s 
m
ea
su
re
d.
 B
ar
 g
ra
ph
s 
sh
ow
in
g 
th
e 
le
ve
ls
 o
f t
he
 p
ro
te
in
s 
in
 e
c1
09
 a
nd
 K
Y
se
70
 c
el
ls
. β
-a
ct
in
 w
as
 u
se
d 
as
 th
e 
in
te
rn
al
 c
on
tr
ol
. D
at
a 
re
pr
es
en
t t
he
 m
ea
n 
± 
sD
 o
f t
hr
ee
 in
de
pe
nd
en
t e
xp
er
im
en
ts
. *
P
0.
05
, *
*P

0.
01
, a
nd
 *
**
P
0.
00
1 
by
 o
ne
-w
ay
 a
n
O
V
a
 a
nd
 T
uk
ey
’s
 p
os
t 
ho
c 
te
st
 t
o 
co
m
pa
re
 t
he
 le
ve
ls
 o
f t
he
 p
ro
te
in
 m
ea
su
re
d 
w
ith
 t
he
 c
on
tr
ol
 c
el
ls
 t
re
at
ed
 w
ith
 t
he
 v
eh
ic
le
 o
nl
y.
A
bb
re
vi
at
io
ns
: c
D
D
O
-M
e,
 m
et
hy
l e
st
er
 o
f 2
-c
ya
no
-3
,1
2-
di
ox
oo
le
an
-1
,9
-d
ie
n-
28
-o
ic
 a
ci
d;
 s
D
, s
ta
nd
ar
d 
de
vi
at
io
n;
 a
n
O
V
a
, a
na
ly
si
s 
of
 v
ar
ia
nc
e;
 h
r,
 h
ou
r.
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1022
Wang et al
normal human epithelial cells is essential for the clinical 
usage of CDDO-Me when a low sensitivity to the drug in 
normal tissues is needed.
Cell cycle control is one of the major regulatory mecha-
nisms of cell growth, and uncontrolled cell division or 
propagation of damaged DNA can contribute to genomic 
instability and tumorigenesis.50 Many anticancer agents have 
been reported to arrest the cell cycle at a specific checkpoint 
and thereby induce the cytotoxicity effect.51 CDDO-Me 
induced G
0
/G
1
 arrest in the breast cancer-associated gene 1 
(BRCA1)-deficient cells, G
2
/M arrest in 4T1 breast cancer 
cells, and severe depletion in the S phase in neuroblastoma 
cells.52–54 In the current study, we observed a G
2
/M arrest in a 
concentration- and time-dependent manner in human ESCC 
cells following treatment with CDDO-Me. The transition 
from G
2
 to M phase of cell cycle is regulated in part by the 
mitosis-promoting factor, which consists of cyclin B1 and 
the activated CDK1 (Cdc2).50 Cdc2 binds to cyclin B1 and 
forms a Cdc2–cyclin complex, which is suppressed by the 
phosphorylation of Tyr15 of Cdc2. Moreover, the inhibition 
of cyclin–CDK complex might be amplified by simultaneous 
upregulation of the p21Waf1/Cip1 protein, a CDK inhibitor.55 
Activated p53 itself can inhibit cell cycle progression by 
regulation of p21Waf1/Cip1.56 In the subsequent experiment, 
we found that CDDO-Me treatment decreased the expression 
of cyclin B1 and Cdc2, and increased the levels of p21Waf1/
Cip1 and p53 in both Ec109 and KYSE70 cells. These results 
provided an explanation for the G
2
/M-arresting effect of 
CDDO-Me on Ec109 and KYSE70 cells.
Next, we evaluated the apoptotic effect of CDDO-Me 
on human ESCC cell using flow cytometry analysis. Con-
sistent with the pro-apoptotic effects in other cancer cell 
lines reported in previous studies,57–59 our data showed that 
CDDO-Me induced concentration- and dose-dependent 
apoptosis in Ec109 and KYSE70 cells. Apoptosis is regulated 
by two major pathways, direct activation of caspase-8 by a 
signaling complex that includes a cell surface receptor and 
activation of caspase-8 via direct signaling transduction, and 
the convergence of the signaling at the mitochondrion, such 
as those mediated by the Bcl-2 family of proteins.60,61 The pro-
teins of the Bcl-2 family are the key regulators of apoptosis, 
exerting both pro- and anti-apoptotic effects.62 Anti-apoptotic 
members of Bcl-2 (Bcl-xl and Bcl-2) can be inhibited by post-
translational modification and/or by increased expression of 
PUMA, which is an essential regulator of p53-mediated cell 
apoptosis.63 The possible molecular mechanisms responsible 
for CDDO-Me-induced apoptosis were explored in the pres-
ent study. The decreased  expression level of the pro-survival 
proteins Bcl-2 and Bcl-xl and increased expression level of 
the pro-apoptotic molecule Bax and its regulator PUMA were 
observed. Caspases are proteins that are highly conserved, 
cysteine-dependent aspartate-specific proteases that play a 
central role in apoptosis initiation and execution. There are 
two types of caspases: initiator caspases including caspases 2, 
8, 9, 10, 11, and 12 and effector caspases including caspases 
3, 6, and 7.64–66 Caspase activation is generally considered 
to be a key mark of apoptosis, playing an important role in 
the induction and regulation of apoptosis.64,66 PARP can be 
activated in cells experiencing stress and/or DNA damage, 
depleting the ATP of a cell and eventually inducing apop-
tosis and autophagy.67 Our study clearly showed that after 
24-hour treatment with CDDO-Me, the expression of cleaved 
caspase-3 and -9 and PARP was significantly increased. 
These data indicate that CDDO-Me induces the apoptosis 
of human ESCC cells through mitochondrial membrane 
dysfunction.
Autophagic cell death that is different from both apop-
tosis and necrosis has independent morphological and bio-
chemical features.34,35,68 So it is considered a second type of 
programmed cell death (sometimes referred to “type II cell 
death”).68 Accumulating evidence has demonstrated that 
various anticancer therapies induce autophagy in different 
cancer cell types.69,70 These findings have shed light from 
different directions on the potential of modulating autophagy 
as a novel therapeutic strategy for malignant diseases. The 
current study showed that a proportion of human ESCC cells 
underwent autophagic cell death in a dose- and time-depen-
dent manner following CDDO-Me treatment, which was 
confirmed by both flow cytometric and confocal microscopy 
analysis. CDDO-Me enhanced the conversion of LC3 from 
cytosolic form (LC3-I) to the proteolytic and lipidated form 
(LC3-II) in Ec109 cells. Additionally, beclin 1 is an essential 
modifier of the autophagic process and is commonly used to 
monitor autophagy activity combined with other biochemical 
factors.33 The upregulation of beclin 1 by CDDO-Me was 
observed in our study.
The kinase mTOR is a critical regulator of autophagy 
induction, with activated mTOR (Akt and MAPK signaling) 
suppressing autophagy and negative regulation of mTOR 
(AMPK and p53 signaling) promoting it.34,71–73 Class III 
PI3K complex, containing hVps34, beclin 1 (a mammalian 
homolog of yeast Atg6), p150 (a mammalian homolog of 
yeast Vps15), and Atg14-like protein (Atg14L or Barkor) or 
ultraviolet irradiation resistance-associated gene (UVRAG), 
is required for the induction of autophagy.33 The Atg genes 
control the autophagosome formation through Atg12-Atg5 
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and LC3-II (Atg8-II) complexes.31 Akt regulates multiple 
biological processes including cell survival, proliferation, 
growth, and glycogen metabolism. Activated Akt trig-
gers activation of the lipid kinase PI3K, which generates 
PIP3 at the plasma membrane.74 Akt binds PIP3 through 
its pleckstrin homology domain, resulting in translocation 
of Akt to the membrane. Akt directly phosphorylates and 
activates mTOR, as well as inhibits the mTOR inhibitor 
proteins PRAS40 and tuberin. Akt promotes cell survival 
directly by its ability to phosphorylate and inactivate sev-
eral pro-apoptotic targets, including Bad, Bim, Bax, and the 
forkhead (FoxO1/3a) transcription factors.74 PTEN, a lipid 
phosphatase that catalyzes the dephosphorylation of PIP3, 
is a major negative regulator of Akt signaling.75 Loss of 
PTEN function has been implicated in many human cancers. 
p38 MAPKs (α, β, γ, and δ) are members of the MAPK family 
that are activated by a variety of environmental stresses and 
inflammatory cytokines.76 As with other MAPK cascades, 
the membrane-proximal component is an MAPK kinase 
kinase (MAPKKK), typically an MAP kinase kinase kinase 
(MEKK) or a mixed lineage kinase. As the inhibition of 
mTOR pathway is the best-known mechanism through which 
autophagy is induced, many other kinases or proteins which 
modulated this pathway and contributed to the regulation of 
autophagic cell death were also evaluated in this study. The 
results showed that CDDO-Me suppressed the phosphoryla-
tion of PI3K and Akt but elevated AMPK, p-p38 MAPK, and 
PTEN expression levels in both Ec109 and KYSE70 cells. 
This will trigger the initiation of autophagy in ESCC cells 
when exposed to CDDO-Me.
Despite marked differences between apoptosis and 
autophagy, recent studies have suggested that there is a cross 
talk between the autophagic and apoptotic pathways.77–80 
Autophagy can be activated in response to anticancer therapy 
by apoptosis-inducing agents that limit drug efficacy, and 
blockage of autophagy can facilitate apoptosis. This illus-
trates that the apoptotic and autophagic response machiner-
ies share common pathways that either link or polarize the 
cellular responses. One example is the interaction between 
anti-apoptotic protein Bcl-2 and autophagy-related protein 
beclin 1. Bcl-2 antagonizes Bax and Bak, preventing apop-
tosis, whereas the interaction between Bcl-2 and beclin 1 
inhibits autophagy.81 Therefore, the Bcl-2 level is of great 
significance for apoptosis and autophagy. As indicated previ-
ously, the mTOR has been confirmed as a key negative regu-
lator of autophagy in mammalian cells.32 In the present study, 
we focused on the modulation of mTOR signaling pathway 
and evaluated the interactions between CDDO-Me-induced 
autophagy and apoptosis using flow cytometric analysis. p38 
MAPK inhibitor SB202190, AMPK inhibitor Compound C, 
Akt inhibitor MK-2206, PI3K inhibitor wortmannin, and 
mTOR inhibitor rapamycin were used in the analysis. We 
found that PI3K and AMPK participated in both the CDDO-
Me-induced apoptosis and autophagy. AMPK plays a key 
role as a master regulator of cellular energy homeostasis.82 
The kinase is activated in response to stresses that deplete 
cellular ATP supplies such as low glucose, hypoxia, isch-
emia, and heat shock. It exists as a heterotrimeric complex 
composed of a catalytic α subunit and regulatory β and γ 
subunits.82 Binding of AMP to the γ subunit allosterically 
activates the complex, making it a more attractive substrate 
for phosphorylation at Thr172 in the activation loop of the 
α subunit by its major upstream AMPK kinase.
ROS are generated intracellularly as byproducts of 
normal aerobic metabolism or as second messengers in 
various signal transduction pathways or in response to 
environmental stress.83 Increased generation of ROS and an 
altered redox status have long been observed in cancer cells, 
and recent studies suggest that modulating the unique redox 
regulatory mechanisms of cancer cells might be an effective 
strategy to eliminate these cells.84 Previous studies have found 
that CDDO-Me inhibited the proliferation of cancer cells via 
the ROS generation.59,85,86 In contrast, the results of the current 
study showed that CDDO-Me attenuated the ROS level in 
human ESCC cells. To elucidate the underlying mechanism, 
the Nrf2 pathway87 that plays a critical role in the antioxida-
tive modulation was evaluated in this study. CDDO-Me has 
been used as an Nrf2 activator in treating the chronic kidney 
disease and showed promise results.11 However, the role of 
Nrf2 pathway activation for CDDO-Me was not well docu-
mented in solid cancer before. Subsequently, we found that 
CDDO-Me induced the nuclear translocation of Nrf2 and 
activated the downstream target genes, such as HO-1, NQO1, 
and GST, especially at the lower concentration. However, for 
the cell signaling pathway hijack effect of cancer, the contri-
bution of Nrf2 pathway activation in the scavenging of ROS 
was less important. As indicated in the “Results” section, 
the reduction level of ROS in Ec109 and KYSE70 cells was 
moderate after the treatment with CDDO-Me.
It is well known that cancer metastasis occurs in many 
steps including vessel formation, cell attachment, adhesion, 
invasion, migration, and proliferation, and these events are 
regulated by extremely complex mechanisms.42 Cell invasion 
is one of the essential steps of cancer metastasis.88 In this 
study, the cell invasion suppression effect of CDDO-Me on 
human ESCC cells was analyzed. Our findings indicated that 
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following treatment with 0.5 µM CDDO-Me for 24 hours, 
the invasive ability of both Ec109 and KYSE70 cells was 
remarkably reduced. Accumulating evidence has shown that 
EMT plays an important role in cancer invasion. To further 
check the underlying mechanism of the suppression of cancer 
cell invasion by CDDO-Me, the EMT process was evaluated 
in the present study. EMT is such process which allows epi-
thelial cells to change their phenotype, acquire mesenchymal 
properties, and increase their capability to migrate.37,39,89 It 
is a fine-tuned process regulated by a number of proteins 
that are strategically distributed in the nuclear and cytosolic 
compartments of cancer cells. A number of different parallel 
signaling pathways interact in the development of EMT.39 
A key feature of EMT is decreased expression of E-cadherin, 
a transmembrane cell adhesion molecule necessary for 
maintenance of intercellular contacts and cellular polarity 
in epithelial tissue, and increased expression of one or more 
of the mesenchymal markers vimentin, fibronectin, and 
N-cadherin.90 The transcription factors Snail, Slug, Twist, 
and ZEB1 play a central role in the induction of EMT and 
downregulation of E-cadherin. In particular, Snail has been 
reported to interact with nuclear β-catenin, promoting activa-
tion of Wnt target genes and further driving EMT.91 More-
over, tight junction proteins ZO-1 and claudin 1 also have a 
contribution role in the EMT process.37 Interestingly, here we 
showed that incubation of CDDO-Me led to a reversion of 
EMT progress, characterized by decreased expression of tran-
scription factors Snail, Slug, and ZEB1, and mesenchymal 
markers vimentin and N-cadherin, and increased expression 
of epithelial markers E-cadherin, and tight junction proteins 
ZO-1 and claudin 1, which was in agreement with the cell 
invasion assay of human ESCC cell lines in vitro. These 
findings suggest a potential role of CDDO-Me in suppression 
of metastasis of ESCC.
A growing body of research demonstrated that, similar 
to normal tissue, some cancers have a hierarchical organiza-
tion where tumorigenic cancer stem cells differentiate into 
non-tumorigenic progenies.41,43 Experimental and clinical 
oncogenomics data provide powerful evidence in support of a 
cancer stem-cell hypothesis and suggest that gene expression 
signatures associated with the stemness state of a cell (defined 
as phenotypes of self-renewal, asymmetric division, and 
pluripotency) might perform critical role in cancer therapy 
resistance.92,93 Oct-4, one of the stem-related transcription 
factors, together with Sox-2 and Nanog, regulates tumor pro-
liferation and self-renewal and maintains stem pluripotency 
of cancer cell.44,46,94 Bmi-1, a member of the polycomb-group 
proteins, was identified as one of the key regulatory proteins 
of “stemness” functions in both normal and cancer stem 
cells.47,95 In the current study, these four stemness markers 
were selected for the evaluation of the inhibitory ability of 
CDDO-Me in cancer stemness. The results showed that 
CDDO-Me suppressed the expression level of these stemness 
markers, especially in the higher concentration and longer 
incubation time. Since stemness reflects the self-renewal 
ability of cancer cells, CDDO-Me may inhibit the growth 
of ESCC via suppression of self-renewal.
Conclusion
In conclusion, we first investigated the anticancer effects 
of CDDO-Me on human ESCC cells. We demonstrated 
that CDDO-Me induced cell cycle arrest, apoptosis, and 
autophagy, and inhibited ROS level, cell invasion, EMT, 
and stemness in ESCC cells. Induction of apoptosis by 
CDDO-Me is via activation of the mitochondrial pathway, 
while the induction of autophagy is via the inhibition of the 
PI3K/Akt/mTOR pathway. CDDO-Me might be a potent 
and promising agent to combat esophageal cancer. Further 
mechanistic studies are needed to elucidate the target network 
of CDDO-Me in ESCC treatment.
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